Nygaard B, Hegedüs L, Bennedbaek F N, Veje A, Faber J O, Hansen J E
Endokrinologisk afdeling F, Amtssygehuset i Herlev.
Ugeskr Laeger. 1998 Sep 7;160(37):5349-52.
Traditional treatment modalities of diffuse nontoxic goitre are thyroid hormone suppression or surgery. When treating nodular nontoxic goitre with 131I treatment, a reduction in thyroid volume to about 50% is seen. In the present study we evaluated the effect of 131I treatment in 21 patients treated for a diffuse nontoxic goitre and followed by evaluation of thyroid volume measured by ultrasound. Thyroid volume declined in all patients from median of 66 ml (range 27-160 ml) to 21 ml (9-108 ml) over a year, a reduction of 62%. Three patients developed hypothyroidism in the follow-up period (14%), one of these had a temporary hyperthyroid fase. In conclusion, 131I treatment of diffuse nontoxic goitre reduces thyroid volume by approximately 60% within 12 months. Hypothyroidism developed in 14% during a limited follow-up period.
弥漫性非毒性甲状腺肿的传统治疗方法是甲状腺激素抑制或手术。用¹³¹I治疗结节性非毒性甲状腺肿时，甲状腺体积可缩小约50%。在本研究中，我们评估了¹³¹I治疗21例弥漫性非毒性甲状腺肿患者的效果，并通过超声测量评估甲状腺体积。一年中，所有患者的甲状腺体积从中位数66毫升（范围27 - 160毫升）降至21毫升（9 - 108毫升），减少了62%。随访期间有3例患者发生甲状腺功能减退（14%），其中1例有短暂的甲状腺功能亢进期。总之，¹³¹I治疗弥漫性非毒性甲状腺肿可在12个月内使甲状腺体积减少约60%。在有限的随访期内，14%的患者发生了甲状腺功能减退。
